Synergistic effect of farnesyl transferase inhibitor lonafarnib combined with chemotherapeutic agents against the growth of hepatocellular carcinoma cells

Hepatocellular carcinoma (HCC) is a common and deadly cancer worldwide and is often refractory to chemotherapy due to the development of multidrug resistance. Lonafarnib is an orally active and potent non-peptidomimetic inhibitor of farnesyl transferase. Here, using in vitro HCC cell models, we demo...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Jialiang, Lian, Yifan, Gu, Yurong, Wang, Hongbo, Gu, Lin, Huang, Yanlin, Zhou, Liang, Huang, Yuehua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739619/
https://www.ncbi.nlm.nih.gov/pubmed/29285232
http://dx.doi.org/10.18632/oncotarget.22086

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5739619/
https://www.ncbi.nlm.nih.gov/pubmed/29285232
http://dx.doi.org/10.18632/oncotarget.22086

Ejemplares similares